CNS Lymphoma

19 clinical trials · Condition

Record	Firm	Date
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma (NCT05351593)	James Rubenstein	2022-06-08
GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma (NCT05242146)	GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	2022-05-24
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (NCT05098613)	University of Colorado, Denver	2021-12-21
Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma (NCT05117814)	Peking University People's Hospital	2021-09-01
A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL (NCT04841434)	Charite University, Berlin, Germany	2021-06-01
Usefulness of Gadovist-enhanced FLAIR Imaging (NCT05293990)	Ryoo, In Seon	2017-02-02
Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate (NCT01319591)	Dana-Farber Cancer Institute	2011-03-01
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma (NCT01182415)	Massachusetts General Hospital	2010-06-01
High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study (NCT01083342)	Samsung Medical Center	2010-01-01
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (NCT00596154)	Memorial Sloan Kettering Cancer Center	2004-12-01

Track CNS Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.